DDInter899 DDInter1577
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment of advanced prostate cancer.[L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022. Relugolix has also been studied in the symptomatic treatment of endometriosis. Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous administration - and therefore provides a less burdensome therapeutic option for patients who might otherwise require clinic visits for administration by healthcare professionals. In addition to its relative ease-of-use, relugolix was shown to be superior in the depression of testosterone levels when compared to [leuprolide], another androgen deprivation therapy used in the treatment of prostate cancer. In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and [norethindrone] under the market name Myfembree for the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Relugolix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enzalutamide
Relugolix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Relugolix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Relugolix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Relugolix {u} may lead to a major life threatening interaction when taken with {v} Ticagrelor
Relugolix {u} may lead to a major life threatening interaction when taken with {v} Elagolix
Relugolix may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Relugolix may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Relugolix may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Relugolix may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Relugolix may lead to a major life threatening interaction when taken with Ticagrelor
Relugolix may lead to a major life threatening interaction when taken with Elagolix